财新传媒
财新英文 > 要闻 > 正文

No New Foreign Additions From Frontline Group of Cancer Drugs to Government Medical Insurance List

2021年01月12日 20:48 来源于 财新网
Authorities and foreign firms failed to reach an agreement at talks about cutting treatment prices
Xiong Xianjun, head of the National Healthcare Security Administration’s medical service administration office.

No imported forms of a key type of cancer drug will be available on China’s public health insurance this year because the government and multinational pharmaceutical firms were unable to strike a deal to set lower prices, a high-level official involved in the negotiations has said.

版面编辑:喻竹杨洋

图片推荐

视听推荐

财新网主编精选版电邮 样例
财新网新闻版电邮全新升级!财新网主编精心编写,每个工作日定时投递,篇篇重磅,可信可引。
订阅